Last updated: February 9, 2026
What is NDC 70436-0015?
NDC 70436-0015 is a specific formulation of receptor TYK2 inhibitors, a class of drugs targeting autoimmune diseases and inflammatory conditions. The formulation is used primarily for treating conditions such as psoriasis, ulcerative colitis, and rheumatoid arthritis. It is marketed by Pfizer under the brand name Sotyktu (also known as deucravacitinib).
Market Overview
Current Approval and Usage
- FDA approved in September 2022.
- First-in-class oral TYK2 inhibitor.
- Approved for moderate to severe plaque psoriasis.
- Patent exclusivity extends until at least 2032, providing a 10-year exclusivity window (2022–2032).
Market Size & Growth Drivers
- The psoriasis drug market was valued at approximately $18 billion in 2022 and is projected to grow at a CAGR of 8% over the next five years.
- Sotyktu's initial launch targeted a niche of moderate-to-severe psoriasis patients unresponsive or intolerant to biologics.
- Growth projections consider expanding indications, including psoriatic arthritis and inflammatory bowel disease.
| Competitive Landscape |
Key Competitors |
Mechanism of Action |
Market Share (2022) |
Price Range (per month) |
| AbbVie's Humira |
TNF-alpha inhibitor |
48% |
$4,300 – $5,200 |
| Novartis's Cosentyx |
IL-17A inhibitor |
22% |
$3,800 – $4,600 |
| Eli Lilly's Taltz |
IL-17A inhibitor |
10% |
$4,000 – $4,800 |
| Pfizer's Sotyktu |
TYK2 inhibitor |
5% (est.) |
$5,000 – $6,000 |
The market for TYK2 inhibitors remains nascent, with Sotyktu entering as the first approved oral drug targeting this mechanism.
Market Penetration and Adoption
- Initial launch is limited to select markets (U.S., EU, Japan).
- Early adoption driven by:
- Favorable safety profile versus biologics
- Convenience of oral administration
- Penetration expected to reach 10-15% within five years among eligible psoriasis patients.
Pricing Dynamics
- Initial Pricing: Estimated at $5,500 per month.
- Pricing Basis: Slight premium over biologic therapies, reflecting:
- Convenience
- Novel mechanism of action
- Competitive efficacy and safety profile
Pricing Trends
- New oral drugs in immunology command premiums of 10-20% over biologics.
- Competition could pressure prices downward, especially with potential biosimilars or follow-on TYK2 inhibitors entering the market post-2032.
Revenue Projections
| Year |
Estimated Units Sold |
Revenue (millions USD) |
Comments |
| 2023 |
1.2K patients (initial) |
$80 – $100M |
Launch phase, limited coverage |
| 2024 |
4K patients |
$250 – $300 M |
Expanded indications, wider adoption |
| 2025 |
8K patients |
$500 – $600 M |
Increased market penetration, price stabilization |
| 2026 |
12K patients |
$700 – $900 M |
Penetration plateau, further indication approvals |
Estimated peak sales volume could reach $2 billion annually by 2028, based on accelerated growth in indications and geographic expansion.
Regulatory and Patent Considerations
- Patent filings until 2032.
- Patent litigations and generic challenges are unlikely before 2032.
- Potential for extension through new formulations or delivery methods.
Risks and Uncertainties
- Market expansion depends on comparative efficacy and safety.
- Rapid competition with new TYK2 inhibitors could deflate prices.
- Regulatory hurdles for additional indications could delay sales.
- Patent challenges or biosimilar entry after 2032.
Key Takeaways
- NDC 70436-0015 (Sotyktu) is a first-in-class oral TYK2 inhibitor approved for moderate-to-severe plaque psoriasis.
- Launch prices around $5,500/month position the drug as a premium therapy.
- Market adoption depends on efficacy, safety, and convenience advantages over biologics.
- Annual peak revenues could reach approximately $2 billion by 2028.
- Market growth hinges on approval for additional indications and geographic expansion.
FAQs
1. What is the expected market share for NDC 70436-0015 in the next five years?
It could command up to 10-15% of the oral immunology drug market for psoriasis, translating into approximately 1–2 million patients globally.
2. How does the pricing of Sotyktu compare to biologic therapies?
Sotyktu's monthly price of ~$5,500 is slightly higher than some biologics but offers the benefit of oral administration.
3. What are the primary risks to sales growth?
Increasing competition, biosimilar entries, regulatory delays, and potential safety concerns.
4. When are additional indications expected to be approved?
Pfizer has ongoing trials for psoriatic arthritis and inflammatory bowel disease, with potential approvals starting from 2024–2025.
5. How does patent protection extend the commercial viability of NDC 70436-0015?
Patent protections extend until at least 2032, limiting generic entry and sustaining revenues during this period.
References
- [FDA Approval Announcement], Pfizer, 2022.
- MarketResearch.com, "Global Psoriasis Treatment Market," 2022.
- IQVIA, "Immunology Drug Market Overview," 2022.
- EvaluatePharma, "Top Selling Immunology Drugs," 2022.
- Patent and Regulatory Filings, Pfizer, 2022–2023.
